Topic: HBV Epidemiology and Outcomes
Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial
TM.G. Kouamé, R. Moh, A. Boyd, A. Badjé, D. Gabillard, J.B. N'takpé, S. Maylin, S.P. Eholié, X. Anglaret, C. Danel
The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa
TT. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson
Impact of antiretroviral therapy on liver stiffness among Zambian adults with HIV-HBV co-infection and HIV mono-infection
M. Vinikoor, E. Sinkala, R. Chilengi, L. Mulenga, B. Chi, Z. Zyambo, C. Hoffmann, M.-A. Davies, TM. Egger, G. Wandeler
Response to Truvada based cART in HIV/HBV co-infected patients in Botswana
TM. Anderson, S. Gaseitsiwe, S. Moyo, K.P. Thami, T. Mohammed, D. Setlhare, T.K. Sebunya, E.A. Powell, J. Makhema, J.T. Blackard, R. Marlink, M. Essex, R.M. Musonda
Improved liver fibrosis scores in treated HBV/HIV co-infected patients in South Africa despite persistent immune dysregulation
TT. Maponga, M. Andersson, J. Taaljaard, C.J. Van Rensburg, W. Preiser, R. Glashoff
Topic: HCV Epidemiology and Natural History
Effect of the timing of hepatitis C virus infection, relative to HIV seroconversion on CD4 T cell and HIV RNA evolution among HIV-positive MSM
TD. van Santen, J. van der Helm, G. Touloumi, N. Pantazis, R. Muga, B. Bartmeyer, J. Gill, E. Sanders, A. Kelleher, R. Zangerle, C. Béguelin, K. Porter, M. Prins, R. Geskus
Hepatitis C prevalence, viral diversity and severity of liver disease in HIV patients in Phnom Penh, Cambodia
TA. De Weggheleire, S. An, I. De Baetselier, S. Teav, V. So, S. Sea, S. Ros, S. Thai, S. Francque, L. Lynen
Extremely low hepatitis C antibody prevalence among high-risk, HIV-positive and HIV-negative men who have sex with men and transgender women from community-based organizations in Thailand
TV. Sapsirisavat, A. Avihingsanon, D. Trachunthong, S. Kerr, J. Jantarapakde, S. Pengnonyang, S. Jitjang, R. Janamnuaysook, P. Mingkwanrungrueng, J. Ohata, A. Sohn, A. Katz, N. Phanuphak
Topic: HCV Testing, Monitoring and Management
Development and validation of a risk score to assist testing for acute HCV infection in HIV-infected MSM
A.M. Newsum, I.G. Stolte, J.T.M. van der Meer, J. Schinkel, M. van der Valk, J.W. Vanhommerig, A. Buvé, M. Danta, A. Hogewoning, M. Prins
Ledipasivr/Sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection
M. Nelson, S. Bhagani, R.H. Hyland, C. Yun, M. Mertens, A. Jackson, W. Zheng, D.M. Brainard, J.G. Mchutchinson, P. Ingliz, T. Lutz, J.K. Rockstroh
Retreatment of HCV/HIV co-infected patients who failed 12 weeks of LDV/SOF
A. Luetkemeyer, C. Cooper, S. Naggie, M. Saag, D. Dieterich, M. Sulkowski, S. Naik, M. Natha, J. Yang, L. Stamm, H. Dvory-Sobol, I. Walker, J. McHutchison
Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study
G. Matthews, J. Neuhaus, J. Rockstroh, L. Peters, F. Gordin, A. Arenas-Pinto, C. Emerson, K. Marks, J. Hidalgo, R. Castro, C. Stephan, N. Kumarasamy, S. Emery
Telaprevir containing triple therapy in acute HCV co-infection: the CHAT study
C. Boesecke, G.J. Singh, S. Scholten, T. Lutz, A. Baumgarten, S. Schneeweiss, A. Trein, M. Rausch, P. Ingiliz, J.K. Rockstroh, M. Nelson
SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies
M. Sulkowski, K. Agarwal, K. Patel, D. Samuel, M. Bourlière, Z. Younes, T. Morgan, S. Strasser, B. Leggett, S. Naik, B. Collins, M. Natha, L. Liu, X. Ding, J. Mcnally, A. Osinusi, D.M. Brainard, J. McHutchison, N. Afdhal, I. Walker, N. Brau
Topic: HCV Treatment Access
Treatment scale-up in Australia to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model
M. Hellard, N. Scott, E. Mcbryde, A. Thompson, J. Doyle
Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access
D. Gotham, M. Barber, J. Fortunak, A. Pozniak, A. Hill
Exposure to various combinations of Harm reduction strategies in relation to HIV and HCV incidences among PWID in Montreal, Canada
J. Bruneau, D. Jutras-Aswad, G. Zang, É. Roy
Increasing HCV Access through Clinical Education: Medical Provider Knowledge and Practice Change Intentions
N. Harris, T. Wilder, K. McKinnon, S.H. Kim, A. Urbina
Community engagement in universal access to DAA hepatitis C treatment: the Portuguese case
D. Simões, R. Freitas, B. dos Santos, R. Fuertes, L. Mendão